Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 190

1.

Hepatitis B core-related antigen (HBcrAg): an alternative to HBV DNA to assess treatment eligibility in Africa.

Shimakawa Y, Ndow G, Njie R, Njai HF, Takahashi K, Akbar SMF, Cohen D, Nayagam S, Jeng A, Ceesay A, Sanneh B, Baldeh I, Imaizumi M, Moriyama K, Aoyagi K, D'Alessandro U, Mishiro S, Chemin I, Mendy M, Thursz MR, Lemoine M.

Clin Infect Dis. 2019 May 17. pii: ciz412. doi: 10.1093/cid/ciz412. [Epub ahead of print]

PMID:
31102406
2.

Trio Haploinsufficiency Causes Neurodevelopmental Disease-Associated Deficits.

Katrancha SM, Shaw JE, Zhao AY, Myers SA, Cocco AR, Jeng AT, Zhu M, Pittenger C, Greer CA, Carr SA, Xiao X, Koleske AJ.

Cell Rep. 2019 Mar 5;26(10):2805-2817.e9. doi: 10.1016/j.celrep.2019.02.022.

3.

Reactive hemophagocytic syndrome in the setting of acute human immunodeficiency virus 1 infection: case report and review of the literature.

Tulloch LG, Younes R, Jeng A.

Int J STD AIDS. 2018 Nov;29(13):1354-1358. doi: 10.1177/0956462418788689. Epub 2018 Aug 16. Review.

PMID:
30114998
4.

Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa.

Shimakawa Y, Njie R, Ndow G, Vray M, Mbaye PS, Bonnard P, Sombié R, Nana J, Leroy V, Bottero J, Ingiliz P, Post G, Sanneh B, Baldeh I, Suso P, Ceesay A, Jeng A, Njai HF, Nayagam S, D'Alessandro U, Chemin I, Mendy M, Thursz M, Lemoine M.

J Hepatol. 2018 Oct;69(4):776-784. doi: 10.1016/j.jhep.2018.05.024. Epub 2018 Jul 1.

5.

Implementation of an in-house quantitative real-time polymerase chain reaction method for Hepatitis B virus quantification in West African countries.

Ghosh S, Sow A, Guillot C, Jeng A, Ndow G, Njie R, Toure S, Diop M, Mboup S, Kane CT, Lemoine M, Thursz M, Zoulim F, Mendy M, Chemin I.

J Viral Hepat. 2016 Nov;23(11):897-904. doi: 10.1111/jvh.12561. Epub 2016 Jun 29.

PMID:
27353593
6.

Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study.

Lemoine M, Shimakawa Y, Njie R, Taal M, Ndow G, Chemin I, Ghosh S, Njai HF, Jeng A, Sow A, Toure-Kane C, Mboup S, Suso P, Tamba S, Jatta A, Sarr L, Kambi A, Stanger W, Nayagam S, Howell J, Mpabanzi L, Nyan O, Corrah T, Whittle H, Taylor-Robinson SD, D'Alessandro U, Mendy M, Thursz MR; PROLIFICA investigators.

Lancet Glob Health. 2016 Aug;4(8):e559-67. doi: 10.1016/S2214-109X(16)30130-9.

7.

Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects.

Papillon JP, Lou C, Singh AK, Adams CM, Ksander GM, Beil ME, Chen W, Leung-Chu J, Fu F, Gan L, Hu CW, Jeng AY, LaSala D, Liang G, Rigel DF, Russell KS, Vest JA, Watson C.

J Med Chem. 2015 Dec 10;58(23):9382-94. doi: 10.1021/acs.jmedchem.5b01545. Epub 2015 Nov 18.

PMID:
26540564
8.

Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors.

Papillon JP, Adams CM, Hu QY, Lou C, Singh AK, Zhang C, Carvalho J, Rajan S, Amaral A, Beil ME, Fu F, Gangl E, Hu CW, Jeng AY, LaSala D, Liang G, Logman M, Maniara WM, Rigel DF, Smith SA, Ksander GM.

J Med Chem. 2015 Jun 11;58(11):4749-70. doi: 10.1021/acs.jmedchem.5b00407. Epub 2015 May 21.

PMID:
25953419
9.

Fyn inhibition rescues established memory and synapse loss in Alzheimer mice.

Kaufman AC, Salazar SV, Haas LT, Yang J, Kostylev MA, Jeng AT, Robinson SA, Gunther EC, van Dyck CH, Nygaard HB, Strittmatter SM.

Ann Neurol. 2015 Jun;77(6):953-71. doi: 10.1002/ana.24394. Epub 2015 Mar 21.

10.

Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects.

Ménard J, Rigel DF, Watson C, Jeng AY, Fu F, Beil M, Liu J, Chen W, Hu CW, Leung-Chu J, LaSala D, Liang G, Rebello S, Zhang Y, Dole WP.

J Transl Med. 2014 Dec 10;12:340. doi: 10.1186/s12967-014-0340-9.

11.

Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors.

Meredith EL, Ksander G, Monovich LG, Papillon JP, Liu Q, Miranda K, Morris P, Rao C, Burgis R, Capparelli M, Hu QY, Singh A, Rigel DF, Jeng AY, Beil M, Fu F, Hu CW, LaSala D.

ACS Med Chem Lett. 2013 Oct 17;4(12):1203-7. doi: 10.1021/ml400324c. eCollection 2013 Dec 12.

12.

Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease.

Cruchaga C, Karch CM, Jin SC, Benitez BA, Cai Y, Guerreiro R, Harari O, Norton J, Budde J, Bertelsen S, Jeng AT, Cooper B, Skorupa T, Carrell D, Levitch D, Hsu S, Choi J, Ryten M, Sassi C, Bras J, Gibbs RJ, Hernandez DG, Lupton MK, Powell J, Forabosco P, Ridge PG, Corcoran CD, Tschanz JT, Norton MC, Munger RG, Schmutz C, Leary M, Demirci FY, Bamne MN, Wang X, Lopez OL, Ganguli M, Medway C, Turton J, Lord J, Braae A, Barber I, Brown K; Alzheimer's Research UK (ARUK) Consortium, Pastor P, Lorenzo-Betancor O, Brkanac Z, Scott E, Topol E, Morgan K, Rogaeva E, Singleton A, Hardy J, Kamboh MI, George-Hyslop PS, Cairns N, Morris JC, Kauwe JSK, Goate AM.

Nature. 2014 Jan 23;505(7484):550-554. doi: 10.1038/nature12825. Epub 2013 Dec 11.

13.

Protein profiling in hepatocellular carcinoma by label-free quantitative proteomics in two west African populations.

Fye HK, Wright-Drakesmith C, Kramer HB, Camey S, Nogueira da Costa A, Jeng A, Bah A, Kirk GD, Sharif MI, Ladep NG, Okeke E, Hainaut P, Taylor-Robinson SD, Kessler BM, Mendy ME.

PLoS One. 2013 Jul 30;8(7):e68381. doi: 10.1371/journal.pone.0068381. Print 2013. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/5330d029-ab4d-447d-837f-99b965956234.

14.

Novel progranulin variants do not disrupt progranulin secretion and cleavage.

Karch CM, Jeng AT, Skorupa T, Cruchaga C, Goate AM.

Neurobiol Aging. 2013 Nov;34(11):2538-40. doi: 10.1016/j.neurobiolaging.2013.05.004. Epub 2013 Jun 4.

15.

GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.

Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D, Bertelsen S, Bailey M, McKean D, Shulman JM, De Jager PL, Chibnik L, Bennett DA, Arnold SE, Harold D, Sims R, Gerrish A, Williams J, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Peskind ER, Galasko D, Fagan AM, Holtzman DM, Morris JC; GERAD Consortium; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Alzheimer Disease Genetic Consortium (ADGC), Goate AM.

Neuron. 2013 Apr 24;78(2):256-68. doi: 10.1016/j.neuron.2013.02.026. Epub 2013 Apr 4.

16.

Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure.

Ng TM, Konopka E, Hyderi AF, Hshieh S, Tsuji Y, Kim BJ, Han SY, Phan DH, Jeng AI, Lou M, Elkayam U.

J Cardiovasc Pharmacol Ther. 2013 Jul;18(4):345-53. doi: 10.1177/1074248413482755. Epub 2013 Mar 27.

PMID:
23538300
17.

Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains.

Karch CM, Jeng AT, Nowotny P, Cady J, Cruchaga C, Goate AM.

PLoS One. 2012;7(11):e50976. doi: 10.1371/journal.pone.0050976. Epub 2012 Nov 30.

18.

Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies.

Karch CM, Jeng AT, Goate AM.

J Biol Chem. 2012 Dec 14;287(51):42751-62. doi: 10.1074/jbc.M112.380642. Epub 2012 Oct 26.

19.

Calcium phosphatase calcineurin influences tau metabolism.

Karch CM, Jeng AT, Goate AM.

Neurobiol Aging. 2013 Feb;34(2):374-86. doi: 10.1016/j.neurobiolaging.2012.05.003. Epub 2012 Jun 6.

20.

The emergence of modularity in biological systems.

Lorenz DM, Jeng A, Deem MW.

Phys Life Rev. 2011 Jun;8(2):129-60. doi: 10.1016/j.plrev.2011.02.003. Epub 2011 Feb 25. Review.

21.

Seroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected Gambians.

Jobarteh M, Malfroy M, Peterson I, Jeng A, Sarge-Njie R, Alabi A, Peterson K, Cotten M, Hall A, Rowland-Jones S, Whittle H, Tedder R, Jaye A, Mendy M.

Virol J. 2010 Sep 15;7:230. doi: 10.1186/1743-422X-7-230.

22.

FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice.

Gamliel-Lazarovich A, Gantman A, Coleman R, Jeng AY, Kaplan M, Keidar S.

J Hypertens. 2010 Sep;28(9):1900-7. doi: 10.1097/HJH.0b013e32833c2197.

PMID:
20699715
23.

Protective effects of a dual endothelin converting enzyme/neutral endopeptidase inhibitor on the development of pulmonary hypertension secondary to cardiac dysfunction in the rat.

Dai ZK, Hsieh CC, Chai CY, Wu JR, Jeng AY, Chou SH, Wu BN, Yeh JL, Chen IJ, Tan MS.

Pediatr Pulmonol. 2010 Nov;45(11):1076-85. doi: 10.1002/ppul.21290.

PMID:
20658482
24.

The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation.

Jeng A, Beheshti M, Li J, Nathan R.

Medicine (Baltimore). 2010 Jul;89(4):217-26. doi: 10.1097/MD.0b013e3181e8d635.

25.

The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.

Adams CM, Hu CW, Jeng AY, Karki R, Ksander G, Lasala D, Leung-Chu J, Liang G, Liu Q, Meredith E, Rao C, Rigel DF, Shi J, Smith S, Springer C, Zhang C.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4324-7. doi: 10.1016/j.bmcl.2010.06.086. Epub 2010 Jun 19.

PMID:
20615692
26.

Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: comparison with the 11beta-hydroxylase inhibitor metyrapone.

Rigel DF, Fu F, Beil M, Hu CW, Liang G, Jeng AY.

J Pharmacol Exp Ther. 2010 Jul;334(1):232-43. doi: 10.1124/jpet.110.167148. Epub 2010 Mar 30.

PMID:
20354176
27.

Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Lin TH, Zheng W, Dole WP.

J Clin Pharmacol. 2010 Apr;50(4):401-14. doi: 10.1177/0091270009343932. Epub 2009 Nov 23.

PMID:
19934029
28.

Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors.

LaSala D, Shibanaka Y, Jeng AY.

Anal Biochem. 2009 Nov 1;394(1):56-61. doi: 10.1016/j.ab.2009.07.025. Epub 2009 Jul 19.

PMID:
19622340
29.

Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats.

Huang BS, White RA, Jeng AY, Leenen FH.

Am J Physiol Regul Integr Comp Physiol. 2009 Apr;296(4):R994-R1000. doi: 10.1152/ajpregu.90903.2008. Epub 2008 Dec 31.

30.

Rare red rash.

Hashmi S, Heidari A, Jeng A.

Am J Med. 2008 Oct;121(10):862-3. doi: 10.1016/j.amjmed.2008.07.005. No abstract available.

PMID:
18823855
31.

Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodelling in rats after myocardial infarction.

Huang BS, White RA, Ahmad M, Tan J, Jeng AY, Leenen FH.

Cardiovasc Res. 2009 Feb 15;81(3):574-81. doi: 10.1093/cvr/cvn222. Epub 2008 Aug 8.

PMID:
18689429
32.

Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone.

Mulder P, Mellin V, Favre J, Vercauteren M, Remy-Jouet I, Monteil C, Richard V, Renet S, Henry JP, Jeng AY, Webb RL, Thuillez C.

Eur Heart J. 2008 Sep;29(17):2171-9. doi: 10.1093/eurheartj/ehn277. Epub 2008 Jun 27.

PMID:
18586661
33.

Central infusion of aldosterone synthase inhibitor prevents sympathetic hyperactivity and hypertension by central Na+ in Wistar rats.

Huang BS, White RA, Ahmad M, Jeng AY, Leenen FH.

Am J Physiol Regul Integr Comp Physiol. 2008 Jul;295(1):R166-72. doi: 10.1152/ajpregu.90352.2008. Epub 2008 May 21.

34.

Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases.

Daull P, Jeng AY, Battistini B.

J Cardiovasc Pharmacol. 2007 Sep;50(3):247-56. Review.

PMID:
17878751
35.
36.

Bronchiolitis: Can objective criteria predict eligibility for brief hospitalization?

Brown L, Reiley DG, Jeng A, Green SM.

CJEM. 2003 Jul;5(4):239-44.

PMID:
17472765
37.

Attenuation of experimental subarachnoid hemorrhage-induced increases in circulating intercellular adhesion molecule-1 and cerebral vasospasm by the endothelin-converting enzyme inhibitor CGS 26303.

Lin CL, Kwan AL, Dumont AS, Su YF, Kassell NF, Wang CJ, Wu SC, Kuo CL, Huang CS, Jeng AY, Liu CS.

J Neurosurg. 2007 Mar;106(3):442-8.

PMID:
17367067
38.

Functional neuroprotective effect of CGS 26303, a dual ECE inhibitor, on ischemic-reperfusion spinal cord injury in rats.

Chou AK, Chen TI, Winardi W, Dai MH, Chen SC, Howng SL, Yen CP, Lin TK, Jeng AY, Kwan AL.

Exp Biol Med (Maywood). 2007 Feb;232(2):214-8.

PMID:
17259328
39.

Endothelin-converting enzyme inhibitors for the treatment of subarachnoid hemorrhage-induced vasospasm.

Lin CL, Winardi W, Jeng AY, Kwan AL.

Neurol Res. 2006 Oct;28(7):721-9. Review.

PMID:
17164035
40.

Serum opacity factor promotes group A streptococcal epithelial cell invasion and virulence.

Timmer AM, Kristian SA, Datta V, Jeng A, Gillen CM, Walker MJ, Beall B, Nizet V.

Mol Microbiol. 2006 Oct;62(1):15-25. Epub 2006 Aug 30.

41.

Prevention and reversal of vasospasm and ultrastructural changes in basilar artery by continuous infusion of CGS 35066 following subarachnoid hemorrhage.

Kwan AL, Lin CL, Yen CP, Winardi W, Su YF, Winardi D, Dai ZK, Jeng AY, Kassell NF, Howng SL, Wang CJ.

Exp Biol Med (Maywood). 2006 Jun;231(6):1069-74.

PMID:
16741051
42.

17beta-estradiol inhibits endothelin-1 production and attenuates cerebral vasospasm after experimental subarachnoid hemorrhage.

Lin CL, Dumont AS, Wu SC, Wang CJ, Howng SL, Huang YF, Wong WY, Kassell NF, Jeng AY, Kwan AL.

Exp Biol Med (Maywood). 2006 Jun;231(6):1054-7.

PMID:
16741048
43.

The effects of debanding on the lung expression of ET-1, eNOS, and cGMP in rats with left ventricular pressure overload.

Chou SH, Chai CY, Wu JR, Tan MS, Chiu CC, Chen IJ, Jeng AY, Chang CI, Kwan AL, Dai ZK.

Exp Biol Med (Maywood). 2006 Jun;231(6):954-9.

PMID:
16741030
44.

Differential change in expression of pulmonary ET-1 and eNOS in rats after chronic left ventricular pressure overload.

Tan MS, Chai CY, Wu JR, Yeh JL, Chen IJ, Kwan AL, Jeng AY, Yang HY, Lee MH, Dai ZK.

Exp Biol Med (Maywood). 2006 Jun;231(6):948-53.

PMID:
16741029
45.

Effects of sildenafil on pulmonary hypertension and levels of ET-1, eNOS, and cGMP in aorta-banded rats.

Dai ZK, Tan MS, Chai CY, Chou SH, Lin PC, Yeh JL, Jeng AY, Chang CI, Chen IJ, Wu JR.

Exp Biol Med (Maywood). 2006 Jun;231(6):942-7.

PMID:
16741028
46.

Triple VPI CGS 35601 reduces high blood pressure in low-renin, high-salt Dahl salt-sensitive rats.

Daull P, Blouin A, Belleville K, Beaudoin M, Arsenault D, Leonard H, Sirois P, Nantel F, Jeng AY, Battistini B.

Exp Biol Med (Maywood). 2006 Jun;231(6):830-3.

PMID:
16741007
47.

The hemodynamic and metabolic profiles of Zucker diabetic fatty rats treated with a single molecule triple vasopeptidase inhibitor, CGS 35601.

Daull P, Blouin A, Beaudoin M, Gadbois S, Belleville K, Cayer J, Berthiaume N, Sirois P, Nantel F, Jeng AY, Battistini B.

Exp Biol Med (Maywood). 2006 Jun;231(6):824-9.

PMID:
16741006
48.

The first preclinical pharmacotoxicological safety assessment of CGS 35601, a triple vasopeptidase inhibitor, in chronically instrumented, conscious, and unrestrained spontaneously hypertensive rats.

Daull P, Lepage R, Benrezzak O, Cayer J, Beaudoin M, Belleville K, Blouin A, Sirois P, Nantel F, Jeng AY, Battistini B.

Drug Chem Toxicol. 2006;29(2):183-202.

PMID:
16707327
49.

CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme.

Battistini B, Daull P, Jeng AY.

Cardiovasc Drug Rev. 2005 Winter;23(4):317-30. Review.

PMID:
16614731
50.

Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.

Daull P, Benrezzak O, Arsenault D, Pheng LH, Blouin A, Cayer J, Beaudoin M, Belleville K, Sirois P, Nantel F, Jeng AY, Battistini B.

Am J Hypertens. 2005 Dec;18(12 Pt 1):1606-13.

PMID:
16364833

Supplemental Content

Support Center